Proposed INN: List 104 <strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong>erteberel(3aS,4R,9bR)-4-(4-hidroxifenil)-1,2,3,3a,4,9bhexahidrociclopenta[c]cromen-8-olagonista de los receptores estrogénicos betaC 18 H 18 O 3 533884-09-2HH HOOHHOetrolizumabum #etrolizumabétrolizumabetrolizumabimmunoglobulin G1-kappa, anti-[Homo sapiens integrinsITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin α4β7,lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) andITGAE_ITGB7 (integrin alphaE (CD103, alphaIEL)_beta7, integrinαEβ7, HML-1], humanized monoclonal antibody;gamma1 heavy chain (1-446) [humanized VH (Homo sapiensIGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homosapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfide with kappa light chain (1’-214’)[humanized V-KAPPA (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];(226-226":229-229")-bisdisulfide dimerimmunomodulatorimmunoglobuline G1-kappa, anti-[Homo sapiens intégrinesITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine α4β7,récepteur d’adressage spécifique des plaques de Peyer, LPAM-1) etITGAE_ITGB7 (intégrine alphaE (CD103, alphaIEL)_bêta7, intégrineαEβ7, HML1)], anticorps monoclonal humanisé;chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiensIGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homosapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];dimère (226-226":229-229")-bisdisulfureimmunomodulateurimmunoglobuline G1-kappa, anti-[integrinas ITGA4_ITGB7 de Homosapiens (integrina alfa4 (CD49d)_beta7, integrina α4β7, molécula deadhesión específica de linfocitos de las placas de Peyer, LPAM-1) eITGAE_ITGB7 (integrina alfaE (CD103, alfaIEL)_beta7, integrinaαEβ7, HML1)], anticuerpo monoclonal humanizado;cadena pesada gamma1 (1-446) [VH humanizada (Homo sapiensIGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -Homosapiens IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];dímero (226-226":229-229")-bisdisulfuroinmunomodulador370
<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong> Proposed INN: List 1041044758-60-2Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGFFIT NNYWGWVRQA PGKGLEWVGY 50ISYSGSTSYN PSLKSRFTIS RDTSKNTFYL QMNSLRAEDT AVYYCARTGS 100SGYFDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG 446Light chain / Chaîne légère / Cadena ligeraDIQMTQSPSS LSASVGDRVT ITCRASESVD DLLHWYQQKP GKAPKLLIKY 50ASQSISGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GNSLPNTFGQ 100GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-95 144-200 261-321 367-42522''-95'' 144''-200'' 261''-321'' 367''-425''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 220-214' 220''-214'''Inter-H-H 226-226'' 229-229''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación297, 297''florbenazinum ( 18 F)florbenazine ( 18 F)florbénazine ( 18 F)florbenazina ( 18 F)(2R,3R,11bR)-9-(3-[ 18 F]fluoropropoxy)-10-methoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-oldiagnostic aid(2R,3R,11bR)-9-(3-[ 18 F]fluoropropoxy)-10-méthoxy-3-(2-méthylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoléin-2-olproduit à usage diagnostique(2R,3R,11bR)-9-(3-[ 18 F]fluoropropoxi)-3-(2-metilpropil)-10-metoxi-1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolin-2-olagente de diagnósticoC 21 H 32 18 FNO 3 956903-29-0HOHCH 3H 3 COHNHCH 3[ 18 F]O371
- Page 1 and 2:
WHO Drug Information Vol. 24, No. 4
- Page 3 and 4:
WHO Drug Information Vol. 24, No. 4
- Page 5 and 6:
WHO Drug Information Vol. 24, No. 4
- Page 7 and 8:
WHO Drug Information Vol. 24, No. 4
- Page 9 and 10:
WHO Drug Information Vol. 24, No. 4
- Page 11 and 12:
WHO Drug Information Vol. 24, No. 4
- Page 13 and 14:
WHO Drug Information Vol. 24, No. 4
- Page 15 and 16:
WHO Drug Information Vol. 24, No. 4
- Page 17 and 18:
WHO Drug Information Vol. 24, No. 4
- Page 19 and 20:
WHO Drug Information Vol. 24, No. 4
- Page 21 and 22:
WHO Drug Information Vol. 24, No. 4
- Page 23 and 24:
WHO Drug Information Vol. 24, No. 4
- Page 25 and 26:
WHO Drug Information Vol. 24, No. 4
- Page 27 and 28:
WHO Drug Information Vol. 24, No. 4
- Page 29 and 30: WHO Drug Information Vol. 24, No. 4
- Page 31 and 32: WHO Drug Information Vol. 24, No. 4
- Page 33 and 34: WHO Drug Information Vol. 24, No. 4
- Page 35 and 36: WHO Drug Information Vol. 24, No. 4
- Page 37 and 38: WHO Drug Information Vol. 24, No. 4
- Page 39 and 40: WHO Drug Information Vol. 24, No. 4
- Page 41 and 42: WHO Drug Information Vol. 24, No. 4
- Page 43 and 44: WHO Drug Information Vol. 24, No. 4
- Page 45 and 46: WHO Drug Information Vol. 24, No. 4
- Page 47 and 48: WHO Drug Information Vol. 24, No. 4
- Page 49 and 50: WHO Drug Information Vol. 24, No. 4
- Page 51 and 52: WHO Drug Information Vol. 24, No. 4
- Page 53 and 54: WHO Drug Information Vol. 24, No. 4
- Page 55 and 56: WHO Drug Information Vol. 24, No. 4
- Page 57 and 58: WHO Drug Information Vol. 24, No. 4
- Page 59 and 60: WHO Drug Information Vol. 24, No. 4
- Page 61 and 62: WHO Drug Information, Vol. 24, No.
- Page 63 and 64: WHO Drug Information, Vol. 24, No.
- Page 65 and 66: WHO Drug Information, Vol. 24, No.
- Page 67 and 68: WHO Drug Information, Vol. 24, No.
- Page 69 and 70: WHO Drug Information, Vol. 24, No.
- Page 71 and 72: WHO Drug Information, Vol. 24, No.
- Page 73 and 74: WHO Drug Information, Vol. 24, No.
- Page 75 and 76: WHO Drug Information, Vol. 24, No.
- Page 77 and 78: WHO Drug Information, Vol. 24, No.
- Page 79: WHO Drug Information, Vol. 24, No.
- Page 83 and 84: WHO Drug Information, Vol. 24, No.
- Page 85 and 86: WHO Drug Information, Vol. 24, No.
- Page 87 and 88: WHO Drug Information, Vol. 24, No.
- Page 89 and 90: WHO Drug Information, Vol. 24, No.
- Page 91 and 92: WHO Drug Information, Vol. 24, No.
- Page 93 and 94: WHO Drug Information, Vol. 24, No.
- Page 95 and 96: WHO Drug Information, Vol. 24, No.
- Page 97 and 98: WHO Drug Information, Vol. 24, No.
- Page 99 and 100: WHO Drug Information, Vol. 24, No.
- Page 101 and 102: WHO Drug Information, Vol. 24, No.
- Page 103 and 104: WHO Drug Information, Vol. 24, No.
- Page 105 and 106: WHO Drug Information, Vol. 24, No.
- Page 107 and 108: WHO Drug Information, Vol. 24, No.
- Page 109 and 110: WHO Drug Information, Vol. 24, No.
- Page 111 and 112: WHO Drug Information, Vol. 24, No.
- Page 113 and 114: WHO Drug Information, Vol. 24, No.
- Page 115 and 116: WHO Drug Information, Vol. 24, No.
- Page 117 and 118: WHO Drug Information, Vol. 24, No.
- Page 119 and 120: WHO Drug Information, Vol. 24, No.
- Page 121 and 122: WHO Drug Information, Vol. 24, No.
- Page 123 and 124: WHO Drug Information, Vol. 24, No.
- Page 125 and 126: WHO Drug Information, Vol. 24, No.
- Page 127 and 128: WHO Drug Information, Vol. 24, No.